Verified source report
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
What happened
According to STAT’s source item, STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B, GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-09T06:48:20+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6BSTAT - 2026-06-09T06:48:20+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.